Griffiths, P. & Reeves, M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat. Rev. Microbiol. 19, 759–773 (2021).
Griffiths, P. D. Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation. Lancet Infect. Dis. 12, 790–798 (2012).
Ljungman, P. et al. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 102, 4255–4260 (2003).
Manicklal, S., Emery, V. C., Lazzarotto, T., Boppana, S. B. & Gupta, R. K. The “silent” global burden of congenital cytomegalovirus. Clin. Microbiol. Rev. 26, 86–102 (2013).
Noyola, D. E. et al. Cytomegalovirus urinary excretion and long term outcome in children with congenital cytomegalovirus infection. Congenital CMV Longitudinal Study Group. Pediatr. Infect. Dis. J. 19, 505–510 (2000).
Nelson, C. S. et al. Immune correlates of protection against human cytomegalovirus acquisition, replication, and disease. J. Infect. Dis. 221, S45–S59 (2020).
Permar, S. R., Schleiss, M. R. & Plotkin, S. A. A vaccine against cytomegalovirus: how close are we? J. Clin. Investig. 135, https://doi.org/10.1172/JCI182317 (2025).
Isaacson, M. K. & Compton, T. Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress. J. Virol. 83, 3891–3903 (2009).
Wille, P. T., Wisner, T. W., Ryckman, B. & Johnson, D. C. Human cytomegalovirus (HCMV) glycoprotein gB promotes virus entry in trans acting as the viral fusion protein rather than as a receptor-binding protein. mBio 4, e00332–00313 (2013).
Bernstein, D. I. et al. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial. Vaccine 34, 313–319 (2016).
Griffiths, P. D. et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 377, 1256–1263 (2011).
Pass, R. F. et al. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med. 360, 1191–1199 (2009).
Gomes, A. C. et al. The cytomegalovirus gB/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread. Nat. Commun. 14, 1041 (2023).
Dupont, L. & Reeves, M. B. Cytomegalovirus latency and reactivation: recent insights into an age old problem. Rev. Med. Virol. 26, 75–89 (2016).
Kamar, N. et al. Predictive factors for cytomegalovirus reactivation in cytomegalovirus-seropositive kidney-transplant patients. J. Med. Virol. 80, 1012–1017 (2008).
Ohlin, M., Sundqvist, V. A., Mach, M., Wahren, B. & Borrebaeck, C. A. Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. J. Virol. 67, 703–710 (1993).
Baraniak, I. et al. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies. Proc. Natl. Acad. Sci. USA 115, 6273–6278 (2018).
Zmasek, C. M., Knipe, D. M., Pellett, P. E. & Scheuermann, R. H. Classification of human Herpesviridae proteins using Domain-architecture Aware Inference of Orthologs (DAIO). Virology 529, 29–42 (2019).
Backovic, M. & Jardetzky, T. S. Class III viral membrane fusion proteins. Curr. Opin. Struct. Biol. 19, 189–196 (2009).
Sharma, S., Wisner, T. W., Johnson, D. C. & Heldwein, E. E. HCMV gB shares structural and functional properties with gB proteins from other herpesviruses. Virology 435, 239–249 (2013).
McGeoch, D. J., Rixon, F. J. & Davison, A. J. Topics in herpesvirus genomics and evolution. Virus Res. 117, 90–104 (2006).
Pauling, L., Corey, R. B. & Branson, H. R. The structure of proteins; two hydrogen-bonded helical configurations of the polypeptide chain. Proc. Natl. Acad. Sci. USA 37, 205–211 (1951).
Jung, J. U., Choi, J. K., Ensser, A. & Biesinger, B. Herpesvirus saimiri as a model for gammaherpesvirus oncogenesis. Semin. Cancer Biol. 9, 231–239 (1999).
Ferreiro, D. U., Komives, E. A. & Wolynes, P. G. Frustration, function and folding. Curr. Opin. Struct. Biol. 48, 68–73 (2018).
Twarock, R., Towers, G. J. & Stockley, P. G. Molecular frustration: a hypothesis for regulation of viral infections. Trends Microbiol. 32, 17–26 (2024).
Kesherwani, V. & Tarang, S. An immunoinformatic approach to universal therapeutic vaccine design against BK virus. Vaccine 37, 3457–3463 (2019).
Luque, F. J. & Camarasa, M. J. HIV-1 Envelope Spike MPER: from a vaccine target to a new druggable pocket for novel and effective fusion inhibitors. ChemMedChem 16, 105–107 (2021).
Lopper, M. & Compton, T. Coiled-coil domains in glycoproteins B and H are involved in human cytomegalovirus membrane fusion. J. Virol. 78, 8333–8341 (2004).
Lyles, D. S., Varela, V. A. & Parce, J. W. Dynamic nature of the quaternary structure of the vesicular stomatitis virus envelope glycoprotein. Biochemistry 29, 2442–2449 (1990).
Libersou, S. et al. Distinct structural rearrangements of the VSV glycoprotein drive membrane fusion. J. Cell Biol. 191, 199–210 (2010).
Chen, J., Zhang, X., Jardetzky, T. S. & Longnecker, R. The Epstein-Barr virus (EBV) glycoprotein B cytoplasmic C-terminal tail domain regulates the energy requirement for EBV-induced membrane fusion. J. Virol. 88, 11686–11695 (2014).
Liu, Y. et al. Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion. Sci. Adv. 7, https://doi.org/10.1126/sciadv.abf3178 (2021).
Lankina, A. et al. Developing a vaccine against human cytomegalovirus: identifying and targeting HCMV’s immunological Achilles’ heel. Vaccines 13, https://doi.org/10.3390/vaccines13050435 (2025).
Musunuri, S., Weidenbacher, P. A. B. & Kim, P. S. Bringing immunofocusing into focus. npj Vaccines 9, 11 (2024).
Lewis, G. K., Finzi, A., DeVico, A. L. & Pazgier, M. Conformational masking and receptor-dependent unmasking of highly conserved Env epitopes recognized by non-neutralizing antibodies that mediate potent ADCC against HIV-1. Viruses 7, 5115–5132 (2015).
Vanarsdall, A. L., Ryckman, B. J., Chase, M. C. & Johnson, D. C. Human cytomegalovirus glycoproteins gB and gH/gL mediate epithelial cell-cell fusion when expressed either in cis or in trans. J. Virol. 82, 11837–11850 (2008).
Schultz, E. P. et al. Human cytomegalovirus gH/gL/gO binding to PDGFRalpha provides a regulatory signal activating the fusion protein gB that can be blocked by neutralizing antibodies. J. Virol. 99, e0003525 (2025).
Nelson, C. S. et al. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. Proc. Natl. Acad. Sci. USA 115, 6267–6272 (2018).
Speckner, A., Glykofrydes, D., Ohlin, M. & Mach, M. Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization. J. Gen. Virol. 80, 2183–2191 (1999).
Ebel, H., Benecke, T. & Vollmer, B. Stabilisation of viral membrane fusion proteins in prefusion conformation by structure-based design for structure determination and vaccine development. Viruses 14, https://doi.org/10.3390/v14081816 (2022).
Cope, A. V. et al. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J. Infect. Dis. 176, 1484–1490 (1997).
Owers, D. S., Webster, A. C., Strippoli, G. F., Kable, K. & Hodson, E. M. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst. Rev. 2013, CD005133 (2013).
Emery, V. C. et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355, 2032–2036 (2000).
Reeves, M. B. & Sinclair, J. H. Circulating dendritic cells isolated from healthy seropositive donors are sites of human cytomegalovirus reactivation in vivo. J. Virol. 87, 10660–10667 (2013).
Norris, M. J. et al. The GATE glycoprotein complex enhances human cytomegalovirus entry in endothelial cells. Nat. Microbiol. 10, 1605–1616 (2025).
Meng, E. C., Pettersen, E. F., Couch, G. S., Huang, C. C. & Ferrin, T. E. Tools for integrated sequence-structure analysis with UCSF Chimera. BMC Bioinform. 7, 339 (2006).
Meng, E. C. et al. UCSF ChimeraX: tools for structure building and analysis. Protein Sci. 32, e4792 (2023).
Li, Z., Jaroszewski, L., Iyer, M., Sedova, M. & Godzik, A. FATCAT 2.0: towards a better understanding of the structural diversity of proteins. Nucleic Acids Res. 48, W60–W64 (2020).
Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493–500 (2024).
Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol. Biol. Evol. 30, 772–780 (2013).
Jespersen, M. C., Peters, B., Nielsen, M. & Marcatili, P. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res. 45, W24–W29 (2017).
Desai, P. & Person, S. Incorporation of the green fluorescent protein into the herpes simplex virus type 1 capsid. J. Virol. 72, 7563–7568 (1998).
Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671–675 (2012).